Follow-up survey following the completion of 'A open-label, randomized controlled study of adjuvant therapy with TAP-144-SR (3M) in premenopausal breast cancer patients'
Latest Information Update: 16 Mar 2020
Price :
$35 *
At a glance
- Drugs Leuprorelin (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- 13 Mar 2020 Status changed from active, no longer recruiting to completed.
- 10 Jan 2014 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan.
- 04 Oct 2011 New trial record